These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16781793)

  • 1. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance.
    González-Ortiz M; Hernández-Salazar E; Kam-Ramos AM; Martínez-Abundis E
    Diabetes Res Clin Pract; 2007 Jan; 75(1):115-8. PubMed ID: 16781793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
    Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.
    Aroda VR; Ciaraldi TP; Burke P; Mudaliar S; Clopton P; Phillips S; Chang RJ; Henry RR
    J Clin Endocrinol Metab; 2009 Feb; 94(2):469-76. PubMed ID: 18984667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.
    Glintborg D; Hermann AP; Andersen M; Hagen C; Beck-Nielsen H; Veldhuis JD; Henriksen JE
    Fertil Steril; 2006 Aug; 86(2):385-97. PubMed ID: 16782094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone prevents reactive hypoglycemia in impaired glucose tolerance.
    Arii K; Ota K; Suehiro T; Ikeda Y; Nishimura K; Kumon Y; Hashimoto K
    Diabetes Res Clin Pract; 2005 Sep; 69(3):305-8. PubMed ID: 16098929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
    N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.
    DeFronzo RA; Tripathy D; Abdul-Ghani M; Musi N; Gastaldelli A
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3774-81. PubMed ID: 24937535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Chlorogenic Acid Administration on Glycemic Control, Insulin Secretion, and Insulin Sensitivity in Patients with Impaired Glucose Tolerance.
    Zuñiga LY; Aceves-de la Mora MCA; González-Ortiz M; Ramos-Núñez JL; Martínez-Abundis E
    J Med Food; 2018 May; 21(5):469-473. PubMed ID: 29261010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome.
    Straznicky NE; Grima MT; Sari CI; Eikelis N; Lambert GW; Nestel PJ; Richards K; Dixon JB; Schlaich MP; Lambert EA
    Metabolism; 2015 Jul; 64(7):797-803. PubMed ID: 25827058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
    Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
    Kernan WN; Inzucchi SE; Viscoli CM; Brass LM; Bravata DM; Shulman GI; McVeety JC; Horwitz RI
    Stroke; 2003 Jun; 34(6):1431-6. PubMed ID: 12730556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
    Forst T; Pfützner A; Lübben G; Weber M; Marx N; Karagiannis E; Koehler C; Baurecht W; Hohberg C; Hanefeld M
    Metabolism; 2007 Apr; 56(4):491-6. PubMed ID: 17379006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
    González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
    J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA; Lewy V; Danadian K; Saad R
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
    Utzschneider KM; Tong J; Montgomery B; Udayasankar J; Gerchman F; Marcovina SM; Watson CE; Ligueros-Saylan MA; Foley JE; Holst JJ; Deacon CF; Kahn SE
    Diabetes Care; 2008 Jan; 31(1):108-13. PubMed ID: 17909087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.
    Espinoza SE; Wang CP; Tripathy D; Clement SC; Schwenke DC; Banerji MA; Bray GA; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Stentz FB; Reaven PD; DeFronzo RA; Musi N
    Age (Dordr); 2016 Dec; 38(5-6):485-493. PubMed ID: 27585671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.